Earticle

The distinctive cellular and mitochondrial dysfunctions of a human epithelial lung cancer cell line (H460) from a human lung fibroblastic normal cell line (MRC5) have been studied by dielectric barrier discharge (DBD) plasma treatment. The DBD plasma device have generated large amount of H2O2 and NOx in culture media which is dependent on plasma exposure time. It is found that the cell number of lung cancer cell H460 has been reduced more than the lung normal cell MRC5 as being increased exposure and incubation time. Also these both cell lines have showed mitochondria fragmentation under 5 minutes' plasma exposure, which is a clue of apoptosis. It is noted in this study that AnnexinV staining has showed not only early apoptosis, but also late apoptosis in lung cancer cell H460. Mitochondria enzyme activity and ATP generation have been also much reduced in lung cancer cell H460. Their mitochondrial membrane potential (${\Delta}{\psi}m$) has been found to be reduced in magnitude and shifted to the induced-potential level of cccp, while MRC5 mitochondrial membrane potential has been shifted slightly to that. These distinctively selective responses of lung cancer cell H460 from lung normal cell MRC5 gives us possibility of applying plasma to cancer therapy.

목적: 마이봄샘 기능이상 환자에서 온열마사지기 KCL 990Ⓡ의 효과를 평가해보고자 하였다. 대상과 방법: 마이봄샘 기능이상 환자 27명 54안을 대상으로 1개월간의 전향적 연구를 시행하였다. 대상 환자들은 1일 2회 KCL 990Ⓡ(한국KCL, 대한민국)을 이용한 온열마사지치료를 시행하였고, 치료전과 치료 1주, 1개월 후의 Ocular Surface Disease Index (OSDI)증상설문조사, 눈물삼투압검사, 눈물막 파괴시간 검사를 시행하였다. Optical Quality Analysis System (OQAS)장비를 이용하여 치료전, 치료 1개월 후 객관적 눈물막 파괴시간을 측정하였다. 결과: OSDI 증상 설문조사, 눈물삼투압, 눈물막 파괴시간 모두 치료 1주 후 유의하게 향상되었고 치료 1개월 후까지 계속 유의하게유지되었다(p＜0.05). 객관적 눈물막 파괴시간도 치료 전에 비하여 치료 1개월 후 유의하게 향상되었다(p＜0.05). 결론: 마이봄샘 기능이상을 동반한 안구건조증 환자에서 KCL 990Ⓡ을 이용한 온열마사지치료는 안구건조 증상의 개선뿐 아니라 눈물막과 안구표면에 기능적 향상을 보이므로 편리하고 효과적인 치료방법이 될 수 있을 것이다.

Purpose: To evaluate the clinical usefulness of KCL 990® for the treatment of dry eye with meibomian gland dysfunction (MGD). Methods: Patients (n = 54 eyes, 27 subjects) diagnosed with dry eye with MGD were recruited for a prospective,one-month clinical trial. Patients received a twice-a-day 15-minute treatment using the KCL 990®. Effectiveness parameters included patient symptom scores using the Ocular Surface Disease Index (OSDI) questionnaires, tear osmolarity measured with TearLab® (TearLab Corporation, San Diego, CA, USA), classical tear break-up time (TBUT), and objective TBUT value using an Optical Quality Analysis System (OQAS®, Visiometrics, Castelldefels, Spain). Data are presented for pre-treatment (baseline) and at 1 week and 1 month post-treatment. An objective TBUT value was estimated in each eye when the optical scattering index (OSI) started to increase consistently, and data were obtained at pretreatment (baseline)and at 1 month post-treatment. Results: The symptom scores on OSDI questionnaires, tear osmolarity, and tear break-up time improved significantly from baseline to one week (p < 0.05). This improvement was maintained with no significant regression at 1 month (p < 0.05). The objective TBUT value decreased significantly at 1 month (p < 0.05). Conclusions: KCL 990® contributed to improve not only signs and symptoms of dry eye with MGD, but also the function of the tear film and ocular surface.